Connect with us


A New Study Tries to Explain What Could be behind blood clot risk with AstraZeneca, J&J vaccines.





  • Given the attention recently over COVID-19 vaccines from AstraZeneca (NASDAQ:AZN) and Johnson & Johnson (NYSE:JNJ) over links to rare blood clots in a small number of people, scientist have been hard at work to find out  just what might cause them?
  • Among Scientist at the forefront of such research is, Andreas Greinacher of Germany’s University of Greifswald and his colleagues who now believe that elements of AstraZeneca’s vaccine can stick to a protein that platelets release during the formation of blood clots, according to the findings of their study.
  • As a result, the body identifies these clumps as foreign invaders, causing reactions that lead platelets to become blood clots.
  • On April 20, Greinacher published research in a preprint that has yet to be peer reviewed that offers an explanation on how the AstraZeneca vaccine might cause the rare blood clots known as vaccine-induced immune thrombotic thrombocytopenia.
  • Because J&J’s vaccine, like AstraZeneca’s, is adenovirus-based, the theory might also apply to cases of blood clots seen with J&J’s shot.
  • During an April 20 news conference about the study, Greinacher said that the theory could be a class effect associated with adenovirus vaccines given that adenoviruses have been associated with platelet activation in other studies.
  • But he cautioned that the benefits of adenovirus vaccines greatly outweigh any potential risks from the rare blood clots.
  • Greinacher added he had reached an agreement with J&J to collaborate on examining its vaccine.
  • On Friday last week, the European Medicines Agency reaffirmed the positive risk-benefit profile of the AstraZeneca vaccine across all age groups and the FDA and CDC lifted a pause in administering the J&J vaccine.


Sign up for our Newsletter

Enter your email and stay on top of things,